Media Center
Filter by:
August 26, 2022
IMPROVE DiCE: A Phase 2a Trial Investigating Ninerafaxstat - A Novel Cardiac Mitotrope for the treatment of Diabetic Cardiomyopathy
August 22, 2022
Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022
March 22, 2022
Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect
March 10, 2022
Imbria Pharmaceuticals Strengthens Executive Leadership Team with New Appointments
July 19, 2021
Imbria Pharmaceuticals Announces initiation of enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the safety, tolerability, and efficacy of IMB-1018972 (IMB-101) in patients with non-obstructive hypertrophic cardiomyopathy
July 05, 2021
IMB-10189721, a novel first-in-class partial fatty acid oxidation (pFOX) inhibitor improves cardiac remodelling and function post-myocardial infarction.
July 05, 2021
Phase 1 safety and tolerability study of IMB-1018972, a novel oral modulator of substrate utilization designed to improve cardiac metabolic efficiency and bioenergetics
June 22, 2021
Imbria Pharmaceuticals announces enrolment of the first 10 patients in IMPROVE-DiCE, an exploratory Phase 2 study investigating the impact of IMB-1018972 on cardiac energetics, metabolism and function in patients with type 2 diabetes
May 17, 2021